

EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: **05.01.83** (51) Int. Cl.³: **C 07 D 211/78,**
A 61 K 31/44
(21) Application number: **79302507.3**
(22) Date of filing: **08.11.79**

(54) **Blood platelet aggregation inhibitory 1-benzyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid derivatives and salts thereof; pharmaceutical compositions thereof; and analogy processes for the manufacture thereof.**

(30) Priority: **17.11.78 GB 4498778**
21.09.79 GB 7932817

(43) Date of publication of application:
28.05.80 Bulletin 80/11

(45) Publication of the grant of the patent:
05.01.83 Bulletin 83/1

(84) Designated Contracting States:
AT BE CH DE FR GB IT LU NL SE

(58) References cited:
DE - A - 2 221 770

Chemical Abstracts vol. 52, no. 11, 10 June 1958
Columbus, Ohio, USA
N. A. PREOBRAZHENSKII et al
"Synthesis of alkaloid arecoline and its homologs" column 9162 c-i

(73) Proprietor: **IMPERIAL CHEMICAL INDUSTRIES PLC**
Imperial Chemical House Millbank
London SW1P 3JF (GB)

(72) Inventor: **Howe, Ralph**
Little Beck
Upton Macclesfield Cheshire (GB)
Inventor: **Mills, Stuart Dennett**
17 Harrington Drive
Gawsworth Macclesfield Cheshire (GB)

(74) Representative: **Smith, Stephen Collyer et al,**
Imperial Chemical Industries PLC Legal
Department: Patents Thames House North
Millbank
London SW1P 4QG (GB)


Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).

Blood platelet aggregation inhibitory 1-benzyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid derivatives and salts thereof; pharmaceutical compositions thereof; and analogy processes for the manufacture thereof

This invention relates to novel carboxylic acid derivatives and, more particularly, it relates to novel 1-benzyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid derivatives which inhibit the aggregation of blood platelets *in vivo* and, therefore, may be of application in the treatment or prophylaxis of thrombosis or occlusive vascular disease.

It is known that various N-benzyl 4,5,6,7-tetrahydrothieno[3,2-c]pyridine and N-benzyl-4,5,6,7-tetrahydrofuro[3,2-c]pyridine derivatives possess antiinflammatory and blood platelet aggregation inhibitory properties (M Podesta *et alia*, *European J. Med. Chem., Chim. Therapeutica*, 1974, 9, 487—490). It is also known that various 1-benzyl-1,2,5,6-tetrahydropyridine-4-carboxylic acid esters are chemical intermediates (West German Offenlegungsschrift No. 2221770 and *Annalen*, 1972, 764, 21—27). We have now discovered that certain novel 1-benzyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid derivatives unexpectedly also possess the property of inhibiting the aggregation of blood platelets *in vivo*, and this is the basis for our invention. Two related compounds, 1-benzyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid methyl and ethyl esters, are known [*Zhur. Obschei. Khim.* 1957, 27, 3162—3170 (*Chemical Abstracts*, 1958, 52, 9162c-i) and *J. Chem. Soc. Chemical Communications*, 1975, 682, respectively] but no useful pharmacological properties have been ascribed to them.

According to the invention there is provided a 1-benzyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid derivative of the formula:—



wherein R¹ is a hydroxy, amino, (1—4C)alkylamino, or di-[(1—4C)alkyl]amino radical, a benzyloxy radical optionally bearing a halogeno substituent, or a (1—6C)alkoxy radical optionally bearing a (1—4C)alkoxy, morpholino or di-[(1—4C)alkyl]amino substituent; and benzene ring A bears one or two substituents independently selected from halogeno, (1—4C)alkyl, cyano, carbamoyl, trifluoromethyl and hydroxy radicals; or a pharmaceutically acceptable salt thereof.

Particular values for R¹ are, by way of example only:—

when it is a (1—4C)alkylamino radical, a methylamino or ethylamino radical;

when it is a di-[(1—4C)alkyl]amino radical, a dimethylamino or diethylamino radical;

when it is a (1—6C)alkoxy radical, a methoxy, ethoxy, propoxy, butoxy or amyloxy radical; and when it is a substituted (1—6C)alkoxy radical, an ethoxy, propoxy, butoxy or amyloxy radical bearing a methoxy, ethoxy, morpholino, dimethylamino or diethylamino substituent.

Particular values for a substituent on benzene ring A are, by way of example only:—

when it is a halogeno radical, a fluoro, chloro or bromo radical; and

when it is a (1—4C)alkyl radical, a methyl, ethyl, n-propyl or isopropyl radical.

Particular values for benzene ring A are, for example, when it is a 2-chlorophenyl, 2-cyanophenyl, 2-carbamoylphenyl, 4-chlorophenyl, 4-bromophenyl, 4-methylphenyl, 4-methylphenyl, 2-trifluoromethylphenyl, 3-cyanophenyl, 4-cyanophenyl, 4-hydroxyphenyl, 3,4-dichlorophenyl or 3,5-dichlorophenyl radical, of which values, 2-cyanophenyl and 2-chlorophenyl are preferred.

The compounds of formula I are sufficiently basic to form addition salts with acids. Particular pharmaceutically acceptable acid-addition salts of compounds of formula I are, for example, salts with inorganic acids, for example with hydrogen chloride, hydrogen bromide, sulphuric acid or phosphoric acid, or salts with organic acids, for example oxalic or citric acid.

In addition, compounds of formula I wherein R¹ is a hydroxy radical can form addition salts with bases. Particular base-addition salts of such compounds of formula I are, for example, alkali or alkaline earth metal salts, for example sodium, potassium, calcium or magnesium salts, aluminium or ammonium salts, or salts with organic bases affording a pharmaceutically acceptable cation, for example with triethanolamine.

Specific groups of compounds of formula I which are of particular interest comprise those compounds of formula I defined above wherein in addition:—

(i) R¹ is a hydroxy radical;

(ii) R¹ is an amino radical;

(iii) R¹ is a (1—6C)alkoxy radical, and in particular a methoxy, ethoxy or butoxy radical;

(iv) benzene ring A bears one or two halogeno substituents; and

(v) benzene ring A bears a cyano or carbamoyl radical;

together in each case with the pharmaceutically acceptable salts thereof as appropriate.

A preferred group of compounds of the invention comprises those compounds of formula I


0011 447

wherein R¹ is a hydroxy, amino or (1—4C)alkoxy radical, and benzene ring A bears a 2-chloro or 2-cyano substituent; or a pharmaceutically acceptable salt thereof.


Specific compounds of formula I are described in the accompanying Examples and, of these, 1-(2-chlorobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid, 1-(2-cyanobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid and the respective methyl esters thereof, or pharmaceutically acceptable salts thereof, are of special interest.

The compounds of formula I may be manufactured by any general process of organic chemistry known to be applicable to the synthesis of analogous pyridine derivatives. Such processes are provided as a further feature of the invention and are illustrated by the following procedures, in which R¹ and benzene ring A have any of the meanings defined hereinbefore:—

a) For a compound of formula I wherein benzene ring A is other than a 2-carbamoylphenyl radical, reacting a compound of the formula:—



20 with a benzyl halide of the formula:—




30 wherein Hal. is a halogeno radical, for example a chloro, bromo or iodo radical.

The process may be conveniently carried out in the presence of a base, for example an alkali metal carbonate or acetate, such as potassium carbonate or sodium acetate, preferably in a suitable solvent or diluent, for example methanol or ethanol, and at a temperature of, for example 20—120°C.

The compound of formula II wherein R¹ is a hydroxy radical is known and the remaining starting materials of formula II may be obtained therefrom in conventional manner.

35 b) For a compound of formula I wherein benzene ring A is other than a 2-carbamoylphenyl radical, reacting a compound of formula II with an aldehyde of the formula:—




45 in the presence of a reducing agent.

A particularly suitable reducing agent is, for example, an inorganic hydride, for example sodium or potassium borohydride, or lithium or sodium cyanoborohydride.

The process is preferably carried out in a solvent or diluent, for example a C₁₋₄-alcohol, for example ethanol and, conveniently, at or near room temperature, for example at 15—30°C.


50 Process (b) is of the reaction type known as reductive amination and as such may proceed wholly or in part *via* an intermediate of the formula:—



formed *in situ* and which is subsequently reduced. It is to be understood that this invention also embraces the separate reduction of an intermediate of formula V produced, for example, by reacting a 65 compound of formula II with an aldehyde of formula IV in the absence of a reducing agent.

0011 447

The aldehydes of formula IV may be obtained by standard procedures of organic chemistry.
 c) For a compound of formula I wherein R¹ is a hydroxy radical, hydrolysing a compound of the formula:—




wherein R² has the same value as R¹ other than a hydroxy radical.

A particularly suitable value for R² is for example, a methoxy, ethoxy, benzyloxy or chlorobenzyloxy radical.

15 The hydrolysis may be carried out in the presence of aqueous acid or base, for example an aqueous mineral acid, such as hydrochloric or sulphuric acid, or an aqueous strong base, such as sodium or potassium hydroxide, may be used. A solvent or diluent, for example ethanol or acetic acid, may be conveniently used, and the process may be performed at a temperature of, for example, 20—120°C.

20 d) For a compound of formula I wherein R¹ is a hydroxy or amino radical and benzene ring A bears a carbamoyl substituent hydrolysing a compound of the formula:—



wherein R³ is a hydroxy, (1—6C)alkoxy or amino radical and benzene ring C has one of the values defined for ring A which is a cyanophenyl radical.

The hydrolysis may be carried out using conventional conditions for the production of amides from nitriles for example using similar reagents and solvents to those described in process (c) hereinabove. However in general shorter reaction times are preferred to minimise further hydrolysis of the amide linkage when formed. It will be understood that when R³ is a (1—6C)alkoxy radical in the compound of formula VII, the final product from the process is nevertheless a compound of formula I wherein R¹ is a hydroxy radical.

35 Whereafter, for a compound of formula I wherein R¹ is other than a hydroxy radical, the corresponding compound of formula I wherein R¹ is a hydroxy radical, or a reactive derivative thereof, for example the corresponding acid chloride, bromide or anhydride, is reacted using well known esterification or amidification procedures and conditions with the appropriate compound of the formula R².H wherein R² has the same values as R¹ other than a hydroxy radical.

40 The pharmaceutically acceptable salts as defined hereinbefore may be made by conventional procedures, by reacting with the appropriate acid or base affording a pharmaceutically acceptable anion or cation respectively.

45 As stated above the compounds of formula I possess the property of inhibiting the aggregation of blood platelets. This property may be demonstrated *in vivo*, using standard tests in laboratory animals, for example, in the following test in rabbits.

50 In this test blood samples are taken by a standard open flow technique from the central ear artery of rabbits. The samples are taken into a 3.8% w/v solution of trisodium citrate as anti-coagulant and then centrifuged at first 150 g, and then at 1000 g, to prepare platelet rich and platelet poor plasma fractions, which are used to calibrate an instrument for measuring light transmittance and thus the amount of platelet aggregation. The extent of platelet aggregation following addition of adenosine 5'-diphosphate (ADP) (final concentration 0.5, 1.0, 2.0, 55 4.0 or 8.0 μM) to the platelet rich plasma fraction is then determined, and the value of maximum aggregation in response to each concentration of ADP is recorded. The rabbits are then dosed orally with test compound, and arterial blood samples are withdrawn at intervals after dosing. The platelet rich plasma fraction is prepared and ADP is added as above, and the extent of aggregation assessed by measuring the light transmittance of the sample. This value is compared with that obtained from the 60 same rabbit before dosing, so that a measure of the extent of inhibition of ADP induced blood platelet aggregation is obtained. By way of example only, the compound 1-(2-chlorobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid showed significant inhibition of the aggregation of blood platelets two hours after an oral dose (as its hydrochloride) of 25 mg/kg. However, in general, compounds of formula I produce significant inhibition in the above test following oral doses of 100 mg/kg., or much less, 65 without any signs of overt toxicity at the active dose.

0011 447

Compounds which inhibit the aggregation of blood platelets, for example acetylsalicylic acid, have been used in the treatment or prophylaxis of thrombosis or occlusive vascular disease, and it is envisaged that the compounds of the present invention will be used in a generally similar manner, and for the same clinical indications.

5 When used to inhibit the aggregation of blood platelets in warm-blooded animals including man, a compound of formula I may be administered at a daily oral dose in the range 1—30 mg./kg. and preferably in the range 1—10 mg./kg., or an equivalent amount of a pharmaceutically acceptable salt thereof. In man these doses are equivalent to daily oral doses of approximately 0.07—2.1 g. and
10 0.07—0.7 g. respectively, or an equivalent amount of a pharmaceutically acceptable salt, given in divided doses if necessary.

The compounds of formula I are preferably administered in the form of pharmaceutical compositions, and according to a further feature of the invention there is provided a pharmaceutical composition which comprises a compound of formula I, or a pharmaceutically acceptable salt thereof as defined hereinbefore, together with a pharmaceutically acceptable diluent or carrier. Such a
15 composition is conveniently in a form suitable for oral administration, for example as a tablet, capsule, aqueous or oily suspension, syrup or elixir. Alternatively it may be in a form suitable for parenteral administration by infusion or injection, for example as a sterile injectable solution or suspension, or in a form suitable for rectal administration, for example as a suppository.

Such compositions may be obtained by conventional procedures and using conventional
20 excipients. A composition for oral administration should preferably contain from 5—500 mg. of active ingredient per unit dose, a composition for parenteral administration, 0.5—20 mg./ml. of active ingredient, and a composition for rectal administration, 50—500 mg. of active ingredient.

A composition of the invention may also conveniently contain one or more agents which can have
25 a beneficial effect on thrombosis or occlusive vascular disease, or on associated conditions, selected from, for example, clofibrate, sulfinpyrazone, and dipyridamole.

The invention is illustrated by the following Examples in which (i), yields are by way of example only and are not to be construed as the maximum attainable; (ii), evaporations were carried out *in vacuo* to dryness where possible, using a rotary evaporator; and (iii), melting points were determined in
30 sealed glass capillary tubes:—

Example 1

Triethylamine (2.2 g.) and 2-chlorobenzyl chloride (1.63 g.) were added to a solution of methyl 1,2,5,6-tetrahydropyridine-3-carboxylate hydrochloride (1.63 g.) in methanol (10 ml.). The solution obtained was kept for 24 hours at 20—25°C. and then evaporated. Water (20 ml.) and 10% w/v
35 sodium carbonate solution were then added to the residue to give a mixture of pH 10. This mixture was extracted with ether (2 x 20 ml.). The combined extracts were washed with water, dried (MgSO₄) and evaporated. The residual oil was dissolved in acetone to give a solution which was treated with a slight excess of ethereal hydrogen chloride. The solid which precipitated was collected by filtration and washed with acetone to give methyl 1-(2-chlorobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylate
40 hydrochloride (1.5 g.) m.p. 171—175°C.

Example 2

A solution of methyl 1-(2-chlorobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylate hydrochloride (0.45 g.) in concentrated hydrochloric acid (10 ml.) was heated at 95—100°C. for 2 hours, cooled and
45 evaporated. The residue was evaporated several times with acetone and toluene to remove remaining traces of water. The solid obtained was stirred with acetone and then collected by filtration to give 1-(2-chlorobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid hydrochloride (0.4 g.), m.p. 208—210°C (dec.).

Example 3

4-Hydroxybenzaldehyde (1.34 g.) and sodium cyanoborohydride (0.7 g.) were added to a solution of methyl 1,2,5,6-tetrahydropyridine-3-carboxylate hydrochloride (3.1 g.) in methanol (30 ml.). The mixture was stirred for 3 days at 25°C., evaporated and water (30 ml.) added to the residue followed by concentrated hydrochloric acid to pH 1. This mixture was extracted with ether (2 x 20 ml.) and the
55 extracts discarded. The aqueous phase was basified to pH 9 with 10% w/v sodium carbonate solution and then extracted with ether (2 x 30 ml.). The combined extracts were dried (MgSO₄) and evaporated. The oil obtained was dissolved in acetone and treated with a slight excess of ethereal hydrogen chloride. The solid which was precipitated was collected by filtration to give methyl 1-(4-hydroxybenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylate hydrochloride (2.05 g.). A portion was recrystallized
60 from methanol and acetone to give pure material of m.p. 212—214°C. (dec.).

Example 4

(Note: all parts are by weight)

A mixture of micro-crystalline cellulose (196 parts) and finely divided 1-(2-chlorobenzyl)-1,2,5,6-
65 tetrahydropyridine-3-carboxylic acid hydrochloride (200 parts) was sieved through a 30 mesh screen

0011447

(British Standard No. 410). Magnesium stearate (60 mesh particle size) (4 parts) was then added and, after thorough mixing, the mixture was compressed into tablets weighing 400 mg. and containing 200 mg. of active ingredient, which may be administered to man for therapeutic purposes.

Using a similar procedure, tablets containing 20, 50, 100 and 400 mg. of active ingredient may be obtained.

Similarly the active ingredient may be replaced by another compound of formula I, for example a compound described in any one of Examples 1, 3, or 5—20.

Examples 5—8

Using a similar procedure to that described in Example 1 but starting from the appropriate benzyl halide of formula III and the appropriate ester of formula II there were obtained:— methyl 1-(2-cyanobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylate hydrochloride (Example 5) m.p. 183—4°C., in 54% yield after recrystallisation from methanol/acetone; ethyl 1-(3,4-dichlorobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylate hydrochloride (Example 6) m.p. 192—9°C., in 76% yield; methyl 1-(4-methylbenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylate hydrochloride (Example 7) m.p. 183—4°C., in 81% yield after recrystallisation from methanol/ethyl acetate; and methyl 1-(3,4-dichlorobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylate hydrochloride (Example 8) m.p. 185—188°C., in 71% yield.

Example 9

Using a similar procedure to that described in Example 2, hydrolysis of methyl 1-(3,4-dichlorobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylate hydrochloride gave 1-(3,4-dichlorobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid, m.p. 240—245°C.

Example 10

A mixture of 1-(3,4-dichlorobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid hydrochloride (2.0 g.) and thionyl chloride (15 ml.) was heated under reflux for 30 minutes. Excess thionyl chloride was removed by evaporation and the residue was mixed with toluene and then evaporated. n-Butyl alcohol (30 ml.) was added to the cooled residual solid and the mixture was stirred at 25°C. for 1 hour, during which time all the solid dissolved. The solution obtained was heated under reflux for 10 minutes and then excess n-butyl alcohol was removed by evaporation. The residue was recrystallised from acetone/ether to give n-butyl 1-(3,4-dichlorobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylate hydrochloride (1.2 g.), m.p. 160—162°C.

Examples 11—15

Using a similar procedure to that described in Example 10 but using the appropriate alcohol or amine, the following esters or amides of formula I (ring A = 3,4-dichlorophenyl) were obtained as their hydrochloride salts (unless otherwise stated).

Example	R ¹	Yield (%)	m.p. (°C.)	Recrystallisation solvent
11	PhCH ₂ O	86	166—169	Me ₂ CO/EtOAc
12	Et ₂ NCH ₂ CH ₂ O	21	208—211*	
13	H ₂ N—	18	145—150 ⁺	iPrOH
14	EtNH—	61	224—228	
15	Et ₂ N—	72	200—202	EtOH/Me ₂ CO

* Dihydrochloride, 1 $\frac{3}{4}$ H₂O

+ Free base, $\frac{1}{4}$ H₂O

Examples 16—18

Using a similar procedure to that described in Example 2 but starting from the appropriate methyl ester, there were obtained: 1-(4-methylbenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid hydrochloride (Example 16) in 71% yield, m.p. 230—6°C (after recrystallisation from ethanol/acetone); and 1-(4-bromobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid hydrochloride (Example 17) in 94% yield, m.p. 248—253°C.

The starting material for Example 17 was obtained using a procedure similar to that described in Example 1 but starting from 4-bromobenzyl chloride to give, methyl 1-(4-bromobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylate hydrochloride, m.p. 200—205°C. (Example 18).

0011 447

Example 19


A mixture of 1,2,5,6-tetrahydropyridine-3-carboxylic acid hydrochloride (4.0 g.), triethylamine (8.2 g.) and 2-cyanobenzylbromide (4.0 g.) in methanol (20 ml.) was heated at 95—100°C. for 3 hours. The mixture was evaporated to dryness and an excess of aqueous sodium carbonate solution added. The mixture was again evaporated to dryness and acidified with 2N hydrochloric acid to pH 2—3. The subsequent mixture was evaporated to dryness. The residue was suspended in toluene (30 ml.) and evaporated to dryness. The resultant solid was dissolved in dry ethanol (10 ml.) and the residue (largely sodium chloride) was discarded. The solution was evaporated and the residue recrystallised from ethanol/ether to give 1-(2-cyanobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid hydrochloride as a solid, m.p. 206—212°C.

Example 20

A mixture of methyl 1-(2-cyanobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylate (0.5 g.) and concentrated hydrochloric acid (5.0 ml.) was heated at 95—100°C. for 1—2 hours. The mixture was evaporated to dryness and the residue was triturated with acetone to give 1-(2-carbamoylbenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid hydrochloride, m.p. 219—222°C. (dec.) after recrystallisation from ethanol/acetone.

Claims for the Contracting States: BE CH DE FR GB IT LU NL SE

1. A 1-benzyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid derivative of the formula:—



wherein R¹ is a hydroxy, amino, (1—4C)alkylamino, or di-[(1—4C)alkyl]amino radical, a benzyloxy radical optionally bearing a halogeno substituent, or a (1—6C)alkoxy radical optionally bearing a (1—4C)alkoxy, morpholine or di-[(1—4C)alkyl]amino substituent; and benzene ring A bears one or two substituents independently selected from halogeno, (1—4C)alkyl, cyano, carbamoyl, trifluoromethyl and hydroxy radicals, or a pharmaceutically acceptable salt thereof.

2. A compound as claimed in claim 1 wherein R¹ is a hydroxy, amino, methylamino, ethylamino, dimethylamino, diethylamino, methoxy, ethoxy, propoxy, butoxy or amyloxy radical, or an ethoxy, propoxy, butoxy or amyloxy radical bearing a methoxy, ethoxy, morpholino, dimethylamino or diethylamino substituent; and wherein benzene ring A bears 1 to 2 substituents independently selected from fluoro, chloro, bromo, methyl, ethyl, n-propyl, isopropyl, cyano, carbamoyl, trifluoromethyl and hydroxy radicals.

3. A compound as claimed in claim 1 or 2 wherein benzene ring A is a 2-chlorophenyl, 2-cyanophenyl, 2-carbamoylphenyl, 4-chlorophenyl, 4-bromophenyl, 4-methylphenyl, 2-trifluoromethylphenyl, 3-cyanophenyl, 4-cyanophenyl, 4-hydroxyphenyl, 3,4-dichlorophenyl or 3,5-dichlorophenyl radical.

4. A compound as claimed in claim 1, 2 or 3 wherein benzene ring A bears one or two halogeno substituents.

5. A compound as claimed in claim 1, 2 or 3 wherein benzene ring A bears a cyano or carbamoyl radical.

6. A compound of the formula I set out in claim 1 wherein R¹ is a hydroxy, amino or (1—4C)alkoxy radical; and benzene ring A bears a 2-chloro or 2-cyano substituent; or a pharmaceutically acceptable salt thereof.

7. 1-(2-Chlorobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid, 1-(2-cyanobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid, or the methyl esters thereof, or a pharmaceutically acceptable salt of said acids or esters.

8. A pharmaceutically acceptable base addition salt of a compound of formula I wherein R¹ is a hydroxy radical as claimed in any preceding claim which is an alkali metal, alkaline earth metal, aluminium or ammonium salt, or a salt with an organic base affording a pharmaceutically acceptable cation.

9. A pharmaceutically acceptable acid addition salt of a compound of formula I as claimed in any of claims 1—7 which is a salt with hydrogen chloride, hydrogen bromide, sulphuric acid, phosphoric acid, oxalic acid or citric acid.

10. A pharmaceutical composition which comprises a compound of formula I or a pharmaceutically acceptable salt thereof as claimed in any preceding claim together with a pharmaceutically acceptable diluent or carrier.


11. A process for the manufacture of a compound of formula I or a pharmaceutically acceptable

0011 447

salt thereof as claimed in any of claims 1—8, wherein R¹ and benzene ring A have any of the meanings specified in any of claims 1—6, characterised by:—

(a) for a compound of formula I wherein benzene ring A is other than a 2-carbamoylphenyl radical, reacting a compound of the formula:—

5




II

10

with a benzyl halide of the formula:—

15




III

20

wherein Hal. is a halogeno radical;

(b) for a compound of formula I wherein benzene ring A is other than a 2-carbamoylphenyl radical, reacting a compound of formula II with an aldehyde of the formula:—

25




IV

30

in the presence of a reducing agent;

(c) for a compound of formula I wherein R¹ is a hydroxy radical, hydrolysing a compound of the formula:—

35



VI


40

wherein R² has the same value as R¹ other than a hydroxy radical; or

45

(d) for a compound of formula I wherein R¹ is a hydroxy or amino radical and benzene ring A bears a carbamoyl radical, hydrolysing a compound of the formula:—

50



VII

55


wherein R³ is a hydroxy, (1—6C)alkoxy, or amino radical and benzene ring C has one of the values defined for ring A which is a cyanophenyl radical; whereafter, for a compound of formula I wherein R¹ is other than a hydroxy radical, a compound of formula I wherein R¹ is a hydroxy radical, or a reactive derivative thereof, is reacted with a compound of the formula R².H wherein R² has the same values as R¹ other than a hydroxy radical using a known esterification or amidification procedure; and whereafter, for a pharmaceutically acceptable base addition salt of a compound of formula I wherein R¹ is a hydroxy radical, such a compound is reacted with a suitable base affording a pharmaceutically acceptable cation; and for a pharmaceutically acceptable acid addition salt, a compound of formula I is reacted with a suitable acid affording a pharmaceutically acceptable anion; in either case, using a conventional procedure.

65

Claims for the Contracting State: AT

1. A process for the manufacture of a 1-benzyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid derivative of the formula:—

5




15 wherein R¹ is a hydroxy, amino, (1—4C)alkylamino, or di-[(1—4C)alkyl]amino radical, a benzyloxy radical optionally bearing a halogeno substituent, or a (1—6C)alkoxy radical optionally bearing a (1—4C)alkoxy, morpholino or di-[(1—4C)alkyl]amino substituent; and benzene ring A bears one or two substituents independently selected from halogeno, (1—4C)alkyl, cyano, carbamoyl, trifluoromethyl and hydroxy radicals; or a pharmaceutically acceptable salt thereof, characterised by:—

20 (a) for a compound of formula I wherein benzene ring A is other than a 2-carbamoylphenyl radical, reacting a compound of the formula:—



30 with a benzyl halide of the formula:—




40 wherein Hal. is a halogeno radical;

(b) for a compound of formula I wherein benzene ring A is other than a 2-carbamoylphenyl radical, reacting a compound of formula II with an aldehyde of the formula:—



50 in the presence of a reducing agent;


(c) for a compound of formula I wherein R¹ is a hydroxy radical, hydrolysing a compound of the formula:—



wherein R² has the same value as R¹ other than a hydroxy radical; or

65 (d) for a compound of formula I wherein R¹ is a hydroxy or amino radical and benzene ring A bears a carbamoyl radical, hydrolysing a compound of the formula:—

0011447



VII

5

10 wherein R³ is a hydroxy, (1—6C)alkoxy or amino radical and benzene ring C has one of the values defined for ring A which is a cyanophenyl radical; whereafter, for a compound of formula I wherein R¹ is a hydroxy radical, or a reactive derivative thereof, is reacted with a compound of the formula R².H wherein R² has the same values as R¹ other than a hydroxy radical using a known esterification or amidification procedure; and for a pharmaceutically acceptable base addition salt of a compound of formula I wherein R¹ is a hydroxy radical, such a compound is reacted with a suitable base affording a pharmaceutically acceptable cation; and for a pharmaceutically acceptable acid addition salt, a compound of formula I is reacted with a suitable acid affording a pharmaceutically acceptable anion; in either case, using a conventional procedure.

2. A process according to part (a) of claim 1 characterised in that the reaction is carried out in the presence of a suitable base at a temperature of 20—120°C.

20 3. A process according to part (b) of claim 1 characterised in that the reducing agent is an inorganic hydride and the reaction is carried out at a temperature of 15—30°C.

4. A process according to part (c) of claim 1 characterised in that the reaction is carried out in the presence of an aqueous mineral acid or an aqueous strong base at a temperature in the range 20—120°C.

25 5. A process according to part (d) of claim 1 characterised in that the reaction is carried out in the presence of an aqueous mineral acid or an aqueous strong base at a temperature in the range 20—120°C.


6. A process according to any preceding claim characterised in that in the starting materials R¹ is a hydroxy, amino or (1—4C)alkoxy radical and benzene ring A bears a 2-chloro or 2-cyano substituent.

30

Patentansprüche für die Vertragsstaaten: BE CH DE FR GB IT LU NL SE

1. 1-Benzyl-1,2,5,6-tetrahydropyridin-3-carbonsäure-Derivat der Formel

35



40

45 worin R¹ für ein Hydroxy-, Amino-, (1—4C)Alkylamino- oder Di-[(1—4C)alkyl]aminoradikal, ein Benzoyloxylradikal, das ggf. einen Halogensubstituenten trägt, oder ein (1—6C)Alkoxyradikal, das ggf. einen (1—4C)Alkoxy-, Morpholino- oder Di-[(1—4C)alkyl]aminosubstituenten trägt, steht, und der Benzolring A ein oder zwei Substituenten trägt, die unabhängig voneinander ausgewählt sind aus Halogeno-, (1—4C)Alkyl-, Cyano-, Carbamoyl-, Trifluoromethyl- und Hydroxyradikalen, oder ein pharmazeutisch zulässiges Salz davon.

2. Verbindung nach Anspruch 1, worin R¹ für ein Hydroxy-, Amino-, Methylamino-, Äthylamino-, Dimethylamino-, Diäthylamino-, Methoxy-, Äthoxy-, Propoxy-, Butoxy- oder Amyloxyradikal oder ein Äthoxy-, Propoxy-, Butoxy- oder Amyloxyradikal, das einen Methoxy-, Äthoxy-, Morpholino-, Dimethylamino- oder Diäthylaminosubstituenten trägt, steht, und worin der Benzolring A ein oder zwei Substituenten trägt, die unabhängig voneinander ausgewählt sind aus Fluoro-, Chloro-, Bromo-, Methyl-, Äthyl-, n-Propyl-, Isopropyl-, Cyano-, Carbamoyl-, Trifluoromethyl- und Hydroxyradikalen.

55 3. Verbindung nach Anspruch 1 oder 2, worin der Benzolring A ein 2-Chlorophenyl-, 2-Cyanophenyl-, 2-Carbamoylphenyl-, 4-Chlorophenyl-, 4-Bromophenyl-, 4-Methylphenyl-, 2-Trifluoromethylphenyl-, 3-Cyanophenyl-, 4-Cyanophenyl-, 4-Hydroxyphenyl-, 3,4-Dichlorophenyl- oder 3,5-Dichlorophenylradikal ist.

4. Verbindung nach Anspruch 1, 2 oder 3, worin der Benzolring A ein oder zwei Halogeno-substituenten trägt.

60 5. Verbindung nach Anspruch 1, 2 oder 3, worin der Benzolring A ein Cyano- oder Carbamoylradikal trägt.

6. Verbindung der Formel I, wie sie in Anspruch 1 angegeben ist, worin R¹ für ein Hydroxy-, Amino- oder (1—4C)Alkoxyradikal steht und der Benzolring A einen 2-Chloro- oder 2-Cyano-substituenten trägt, oder ein pharmazeutisch zulässiges Salz davon.

65

7. 1-(2-Chlorobenzyl)-1,2,5,6-Tetrahydropyridin-3-carbonsäure, 1-(2-Cyanobenzyl)-1,2,5,6-tetrahydropyridin-3-carbonsäure oder die Methylester davon oder ein pharmazeutisch zulässiges Salz dieser Säuren oder Ester.


8. Pharmazeutisch zulässiges Basenadditionssalz einer Verbindung der Formel I, worin R¹ für ein Hydroxyradikal steht, wie es in einem der vorherigen Ansprüche beansprucht ist, bei welchem es sich um ein Alkalimetall-, Erdalkalimetall-, Aluminium- oder Ammoniumsalz oder um ein Salz mit einer organischen Base, die ein pharmazeutisch zulässiges Kation liefert, handelt.

9. Pharmazeutisch zulässiges Säureadditionssalz einer Verbindung der Formel I, wie es in einem der Ansprüche 1 bis 7 beansprucht ist, wobei es sich um ein Salz mit Salz-, Bromwasserstoff-, Schwefel-, Phosphor-, Oxal- oder Zitronensäure handelt.


10. Pharmazeutisch Zusammensetzung, welche eine Verbindung der Formel I oder ein pharmazeutisch zulässiges Salz davon, wie es in einem der vorhergehenden Ansprüche beansprucht wird, gemeinsam mit einem pharmazeutisch zulässigen Verdünnungsmittel oder Trägermittel enthält.

11. Verfahren zur Herstellung einer Verbindung der Formel I oder eines pharmazeutisch zulässigen Salzes davon, wie es in einem der Ansprüche 1 bis 8 beansprucht wird, worin R¹ und der Benzolring A eine der in einem der Ansprüche 1 bis 6 angegebenen Bedeutungen haben, dadurch gekennzeichnet, daß man

(a) für eine Verbindung der Formel I, worin der Benzolring A etwas anderes ist als ein 2-Carbamoylphenylradikal, eine Verbindung der Formel




mit einem Benzylhalogenid der Formel




worin Hal für ein Halogenoradikal steht, umsetzt;

(b) für eine Verbindung der Formel I, worin der Benzolring A etwas anderes ist als ein 2-Carbamoylphenylradikal, eine Verbindung der Formel



in Gegenwart eines Reduktionsmittels umsetzt;


(c) für eine Verbindung der Formel I, worin R¹ für ein Hydroxyradikal steht, eine Verbindung der Formel



worin R² den gleichen Wert wie R¹ mit Ausnahme eines Hydroxyradikals hat, hydrolysiert; oder

(d) für eine Verbindung der Formel I, worin R¹ für ein Hydroxy- oder Aminoradikal steht und der Benzolring A ein Carbamoylradikal trägt, eine Verbindung der Formel

0011 447




10 hydrolysiert, worin R³ für ein Hydroxy-, (1—6C)Alkoxy- oder Aminoradikal steht und der Benzolring C einen der für den Ring A definierten Werte, der ein Cyanophenylradikal ist, aufweist; worauf für eine Verbindung der Formel I, worin R¹ etwas anderes als ein Hydroxyradikal ist, eine Verbindung der Formel I, worin R¹ ein Hydroxyradikal ist, oder ein reaktives Derivat davon mit einer Verbindung der Formel R²H, worin R² die gleichen Werte wie R¹ mit Ausnahme eines Hydroxyradikals aufweist, unter Verwendung eines bekannten Veresterungs- oder Amidisierungsverfahrens umgesetzt wird; und worauf für ein pharmazeutisch zulässiges Basenadditionssalz einer Verbindung der Formel I, worin R¹ für ein Hydroxyradikal steht, eine solche Verbindung mit einer geeigneten Base, die ein pharmazeutisch zulässiges Kation liefert, umgesetzt wird, und für ein pharmazeutisch zulässiges Säureadditionssalz eine Verbindung der Formel I mit einer geeigneten Säure, die ein pharmazeutisch zulässiges Anion liefert, umgesetzt wird, wobei in beiden Fällen herkömmliche Verfahren verwendet werden.

20 **Patentansprüche für den Vertragsstaat: AT**

1. Verfahren zur Herstellung eines 1-Benzyl-1,2,5,6-tetrahydropyridin-3-carbonsäure-Derivats der Formel

25




35 worin R¹ für ein Hydroxy-, Amino-, (1—4C)Alkylamino- oder Di[(1—4C)alkyl]aminoradikal, ein Benzyloxylradikal, das ggf. einen Halogenosubstituenten trägt, oder ein (1—6C)Alkoxyradikal, das ggf. einen (1—4C)Alkoxy-, Morpholino- oder Di-[(1—4C)alkyl]aminosubstituenten trägt, steht, und der Benzolring A ein oder zwei Substituenten trägt, die unabhängig voneinander ausgewählt sind aus Halogeno-, (1—4C)Alkyl-, Cyano-, Carbamoyl-, Trifluoromethyl- und Hydroxyradikalen, oder eines pharmazeutisch zulässigen Salzes davon, dadurch gekennzeichnet, daß man

40 (a) für eine Verbindung der Formel I, worin der Benzolring A etwas anderes ist als ein 2-Carbamoylphenylradikal, eine Verbindung der Formel



50 mit einem Benzylhalogenid der Formel




worin Hal für ein Halogenoradikal steht, umsetzt;

60 (b) für eine Verbindung der Formel I, worin der Benzolring A etwas anderes ist als ein 2-Carbamoylphenylradikal, eine Verbindung der Formel II mit einem Aldehyd der Formel

65

0011 447




IV

5

in Gegenwart eines Reduktionsmittels, umsetzt;

(c) für eine Verbindung der Formel I, worin R¹ für ein Hydroxyradikal steht, eine Verbindung der Formel

10




VI

15

worin R² den gleichen Wert wie R¹ mit Ausnahme eines Hydroxyradikals hat, hydrolysiert; oder

(d) für eine Verbindung der Formel I, worin R¹ für ein Hydroxy- oder Aminoradikal steht und der Benzolring A ein Carbamoylradikal trägt, eine Verbindung der Formel

20



VII

25

hydrolysiert, worin R³ für ein Hydroxy-, (1—6C)Alkoxy- oder Aminoradikal steht und der Benzolring C einen der für den Ring A definierten Werte, der ein Cyanophenylradikal ist, aufweist; worauf für eine Verbindung der Formel I, worin R¹ etwas anderes als ein Hydroxyradikal ist, eine Verbindung der Formel I, worin R¹ ein Hydroxyradikal ist, oder ein reaktives Derivat davon mit einer Verbindung der Formel R²H, worin R² die gleichen Werte wie R¹ mit Ausnahme eines Hydroxyradikals aufweist, unter Verwendung eines bekannten Veresterungs- oder Amidisierungsverfahrens umgesetzt wird; und worauf für ein pharmazeutisch zulässiges Basenadditionssalz einer Verbindung der Formel I, worin R¹ für ein Hydroxyradikal steht, eine solche Verbindung mit einer geeigneten Base, die ein pharmazeutisch zulässiges Kation liefert, umgesetzt wird, und für ein pharmazeutisch zulässiges Säureadditionssalz eine Verbindung der Formel I mit einer geeigneten Säure, die ein pharmazeutisch zulässiges Anion liefert, umgesetzt wird, wobei in beiden Fällen herkömmliche Verfahren verwendet werden.

2. Verfahren nach Teil (a) von Anspruch 1, dadurch gekennzeichnet, daß die Reaktion in Gegenwart einer geeigneten Base bei einer Temperatur von 20 bis 120°C ausgeführt wird.

3. Verfahren nach Teil (b) von Anspruch 1, dadurch gekennzeichnet, daß das Reduktionsmittel ein anorganisches Hydrid ist und daß die Reaktion bei der Temperatur von 15 bis 30°C ausgeführt wird.

4. Verfahren nach Teil (c) von Anspruch 1, dadurch gekennzeichnet, daß die Reaktion in Gegenwart einer wäßrigen Mineralsäure oder einer wäßrigen starken Base bei einer Temperatur im Bereich von 20 bis 120°C ausgeführt wird.

5. Verfahren nach Teil (d) von Anspruch 1, dadurch gekennzeichnet, daß die Reaktion in Gegenwart einer wäßrigen Mineralsäure oder einer wäßrigen starken Base bei einer Temperatur im Bereich von 20 bis 120°C ausgeführt wird.


6. Verfahren nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß im Ausgangsmaterial R¹ für ein Hydroxy-, Amino- oder (1—4C)Alkoxyradikal steht und der Benzolring A einen 2-Chloro- oder 2-Cyanosubstituenten trägt.

Revendications pour les États Contractants: BE CH DE FR GB IT LU NL SE

55

1. Un dérivé d'acide 1-benzyl-1,2,5,6-tétrahydropyridine-3-carboxylique de formule

60



I

65

dans laquelle R¹ est un radical hydroxy, amino, (1—4C)alkylamino, ou di-[(1—4C)alkyl]amino, un radical benzyloxy portant éventuellement un substituant halogéno, ou un radical (1—6C)alkoxy portant éventuellement un substituant (1—4C)-alkoxy, morpholino ou di-[(1—4C)alkyl]amino; et le noyau benzénique A porte un ou deux substituants choisis indépendamment entre des radicaux halogéno, (1—4C)alkyle, cyano, carbamoyle, trifluorométhyle et hydroxy, ou un sel pharmaceutiquement acceptable de ce dérivé.

2. Composé suivant la revendication 1, dans lequel R¹ est un radical hydroxy, amino, méthylamino, éthylamino, diméthylamino, diéthylamino, méthoxy, éthoxy, propoxy, butoxy ou amyloxy ou un radical éthoxy, propoxy, butoxy ou amyloxy portant un substituant méthoxy, éthoxy, morpholino, diméthylamino ou diéthylamino; et le noyau benzénique A porte 1 ou 2 substituants choisis indépendamment entre des radicaux fluoro, chloro, bromo, méthyle, éthyle, n-propyle, isopropyle, cyano, carbamoyle, trifluorométhyle et hydroxy.

3. Composé suivant la revendication 1 ou 2, dans lequel le noyau benzénique A est un radical 2-chlorophényle, 2-cyanophényle, 2-carbamoylphényle, 4-chlorophényle, 4-bromophényle, 4-méthylphényle, 2-trifluorométhylphényle, 3-cyanophényle, 4-cyanophényle, 4-hydroxyphényle, 3,4-dichlorophényle ou 3,5-dichlorophényle.

4. Composé suivant la revendication 1, 2 ou 3, dans lequel le noyau benzénique A porte 1 ou 2 substituants halogéno.

5. Composé suivant la revendication 1, 2 ou 3, dans lequel le noyau benzénique A porte un radical cyano ou carbamoyle.

6. Composé de formule I représentée dans la revendication 1, dans lequel R¹ est un radical hydroxy, amino ou (1—4C)-alkoxy; et le noyau benzénique A porte un substituant 2-chloro ou 2-cyano; ou un sel pharmaceutiquement acceptable de ce composé.

7. L'acide 1-(2-chlorobenzyl)-1,2,5,6-tétrahydropyridine-3-carboxylique, l'acide 1-(2-cyanobenzyl)-1,2,5,6-tétrahydropyridine-3-carboxylique ou leurs esters méthyliques, ou un sel pharmaceutiquement acceptable desdits acides ou esters.

8. Un sel d'addition de base pharmaceutiquement acceptable d'un composé de formule I dans laquelle R¹ est un radical hydroxy suivant l'une quelconque des revendications précédentes, qui est un sel de métal alcalin, un sel de métal alcalino-terreux, un sel d'aluminium ou un sel d'ammonium ou un sel formé avec une base organique apportant un cation pharmaceutiquement acceptable.

9. Un sel d'addition d'acide pharmaceutiquement acceptable d'un composé de formule I suivant l'une quelconque des revendications 1 à 7, qui est un sel formé avec du chlorure d'hydrogène, du bromure d'hydrogène, de l'acide sulfurique, de l'acide phosphorique, de l'acide oxalique ou de l'acide citrique.

10. Composition pharmaceutique, qui comprend un composé de formule I ou un sel pharmaceutiquement acceptable de ce composé suivant l'une quelconque des revendications précédentes, conjointement avec un diluant ou support pharmaceutiquement acceptable.

11. Procédé de production d'un composé de formule I ou d'un sel pharmaceutiquement acceptable de ce composé suivant l'une quelconque des revendications 1 à 8, dans lequel R¹ et le noyau benzénique A ont l'une quelconque des définitions précisées dans l'une quelconque des revendications 1 à 6, caractérisé par:

(a) pour un composé de formule I dans laquelle le noyau benzénique A représente autre chose qu'un radical 2-carbamoylphényle, la réaction d'un composé de formule:



II


avec un halogénure de benzyle de formule:



III

dans laquelle Hal est un radical halogéno;

(b) pour un composé de formule I dans laquelle le noyau benzénique A représente autre chose qu'un radical 2-carbamoylphényle, la réaction d'un composé de formule II avec un aldéhyde de formule:




IV

5

en présence d'un agent réducteur;

(c) pour un composé de formule I où R¹ est un radical hydroxy, l'hydrolyse d'un composé de formule:

10




VI

15

dans laquelle R² a la même valeur que R¹, autre qu'un radical hydroxy; ou

(d) pour un composé de formule I dans laquelle R¹ est un radical hydroxy ou amino et le noyau benzénique A porte un radical carboxyle, hydrolyse d'un composé de formule:

20



VII


25

30 dans laquelle R³ est un radical hydroxy, (1—6C)-alkoxy ou amino et le noyau benzénique C a l'une des valeurs définies pour le noyau A qui est un radical cyanophényle; après quoi, pour un composé de formule I dans laquelle R¹ représente autre chose qu'un radical hydroxy, un composé de formule I, dans laquelle R¹ est un radical hydroxy, ou un dérivé réactif de ce composé est amené à réagir avec un composé de formule R².H dans laquelle R² a les mêmes valeurs que R¹ autres qu'un radical hydroxy en
 35 utilisant un procédé connu d'estérification ou d'amidation; puis, pour obtenir un sel d'addition de base pharmaceutiquement acceptable d'un composé de formule I dans laquelle R¹ est un radical hydroxy, un tel composé est amené à réagir avec une base convenable apportant un cation pharmaceutiquement acceptable; et pour obtenir un sel d'addition d'acide pharmaceutiquement acceptable, un composé de formule I est amené à réagir avec un acide convenable apportant un anion pharmaceutiquement
 40 acceptable; en utilisant dans les deux cas un mode opératoire classique.

Revendications pour l'Etat Contractant: AT

1. Procédé de production d'un dérivé d'acide 1-benzyl-1,2,5,6-tétrahydropyridine-3-carboxylique de formule:

45



I

50


55

dans laquelle R¹ est un radical hydroxy, amino, (1—4C)alkylamino, ou di-[(1—4C)alkyl]amino, un radical benzyloxy portant éventuellement un substituant halogéno, ou un radical (1—6C)alkoxy portant éventuellement un substituant (1—4C)alkoxy, morpholino ou di-[(1—4C)alkyl]amino; et le noyau benzénique A porte un ou deux substituants choisis entre des radicaux halogéno, (1—AC) alkyle, cyano, carboxamido, trifluorométhyle et hydroxy, ou d'un sel pharmaceutiquement acceptable de ce dérivé, caractérisé par:

60

(a) la réaction d'un composé de formule:


65



II

5

avec un halogénure de benzyle de formule:




III

10

15

dans laquelle Hal est un radical halogéno;

(b) la réaction d'un composé de formule II avec un aldéhyde de formule:




IV

20

25

en présence d'un agent réducteur;

(c) pour un composé de formule I où R¹ est un radical hydroxy, l'hydrolyse d'un composé de formule:




VI

35

dans laquelle R² a la même valeur que R¹, autre qu'un radical hydroxy; ou

(d) pour un composé de formule I dans laquelle R¹ est un radical hydroxy ou amino et le noyau benzénique A porte un radical carboxamido, l'hydrolyse d'un composé de formule:



VII

45

50 dans laquelle R³ est un radical hydroxy, (1—6C)alkoxy ou amino et le noyau benzénique C a l'une des valeurs définies pour le noyau A qui est un radical cyanophényle; après quoi, pour un composé de formule I dans laquelle R¹ représente autre chose qu'un radical hydroxy, un composé de formule I, dans laquelle R¹ est un radical hydroxy, ou un dérivé réactif de ce composé est amené à réagir avec un composé de formule R².H dans laquelle R² a les mêmes valeurs que R¹ autres qu'un radical hydroxy en utilisant un procédé connu d'estérification ou d'amidation; et, pour obtenir un sel d'addition de base pharmaceutiquement acceptable d'un composé de formule I dans laquelle R¹ est un radical hydroxy, un tel composé est amené à réagir avec une base convenable apportant un cation pharmaceutiquement acceptable; et pour obtenir un sel d'addition d'acide pharmaceutiquement acceptable, un composé de formule I est amené à réagir avec un acide convenable apportant un anion pharmaceutiquement acceptable; en utilisant dans les deux cas un mode opératoire classique.

2. Procédé suivant la partie (a) de la revendication 1, caractérisé en ce que la réaction est conduite en présence d'une base convenable à une température de 20 à 120°C.

3. Procédé suivant la partie (b) de la revendication 1, caractérisé en ce que l'agent réducteur est un hydrure inorganique et la réaction est conduite à une température de 15 à 30°C.

65

0011 447

4. Procédé suivant la partie (c) de la revendication 1, caractérisé en ce que la réaction est conduite en présence d'un acide minéral aqueux ou d'une base forte aqueuse à une température comprise dans la plage de 20 à 120°C.

5. Procédé suivant la partie (d) de la revendication 1, caractérisé en ce que la réaction est conduite en présence d'un acide minéral aqueux ou d'une base forte aqueuse à une température comprise dans la plage de 20 à 120°C pendant une durée de réaction relativement courte.

6. Procédé suivant l'une quelconque des revendications précédentes, caractérisé en ce que dans les matières de départ, R¹ est un radical hydroxy, amino ou (1—4C)alkoxy et le noyau benzénique A porte un substituant 2-chloro ou 2-cyano.

10

15

20

25

30

35

40

45

50

55

60

65